Dateline — WALTHAM, Mass., November 11, 2025:
Zenas BioPharma, Inc. (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company dedicated to developing transformative therapies for autoimmune diseases, has announced that its management team will present at the Jefferies Global Healthcare Conference in London on November 18, 2025, and the 8th Annual Evercore Healthcare Conference on December 3, 2025. This participation reinforces Zenas BioPharma’s growing influence in the biopharmaceutical industry and its commitment to advancing next-generation autoimmune therapeutics through scientific excellence and global collaboration.
Science Significance
Zenas BioPharma’s work is a strong example of how science-driven innovation is redefining autoimmune therapy. The company’s lead molecule, obexelimab, is a bifunctional monoclonal antibody designed to target both CD19 and FcγRIIb, thereby inhibiting pathogenic B-cell activity without depleting the cells. This mechanism offers a safer and more precise approach to managing complex autoimmune diseases. Meanwhile, orelabrutinib, a highly selective CNS-penetrant BTK inhibitor, is poised to become a potential best-in-class therapy targeting both peripheral and central nervous system inflammation. Zenas’s pipeline of innovative molecules and preclinical assets, including TYK2 and IL-17AA/AF inhibitors, highlights a deep commitment to translational science and precision immunology.
Regulatory Significance
As a clinical-stage biopharmaceutical company, Zenas operates under stringent global regulatory frameworks that govern Good Clinical Practice (GCP) and Good Manufacturing Practice (GMP). The company’s clinical development programs are built on rigorous quality assurance protocols, reflecting adherence to FDA, EMA, and NMPA guidelines. Its lead assets—obexelimab and orelabrutinib—are designed with regulatory compliance and patient safety at their core, leveraging validated data and reproducible clinical endpoints. Zenas’s approach underscores how regulatory excellence and science integrity can coexist to accelerate the delivery of novel, high-quality biologic therapies for patients in need.
Advertisement
Business Significance
The company’s participation in premier investor conferences represents a strategic opportunity to showcase its robust therapeutic pipeline and global commercial vision. These events allow Zenas BioPharma to engage directly with the investment community, sharing updates on late-stage clinical assets, strategic partnerships, and potential market expansion. The company’s disciplined acquisition and development model enables it to identify promising therapeutic candidates worldwide, positioning Zenas as an emerging leader in the autoimmune and immunology segments. Such engagements not only elevate its investor profile but also reinforce business confidence in Zenas’s long-term growth strategy and innovative capabilities.
Patients’ Significance
For patients living with chronic and debilitating autoimmune diseases, Zenas’s therapies represent hope for safer, more targeted treatment options. The company’s bifunctional antibody platform is designed to minimize immune suppression while maximizing therapeutic efficacy, improving both safety profiles and quality of life. By focusing on self-administered subcutaneous formulations and oral small-molecule drugs, Zenas is making treatments more accessible and patient-friendly, addressing one of the most pressing needs in autoimmune care—balancing efficacy with convenience. This commitment to patient-centric innovation sets a new benchmark for biopharmaceutical development.
Policy Significance
Zenas BioPharma’s R&D and clinical strategies align with evolving global health policy priorities that promote precision medicine, equitable access, and regulatory harmonization. As global regulators push for faster approvals and adaptive trial designs for autoimmune therapeutics, Zenas’s model supports this transformation. The company’s cross-border clinical programs and international partnerships contribute to shaping a policy environment that values innovation, transparency, and collaboration. Its efforts also reflect the growing synergy between scientific research, regulatory modernization, and patient access frameworks that define the next era of biopharmaceutical development.
Through its participation in the Jefferies Global Healthcare Conference and the Evercore Healthcare Conference, Zenas BioPharma reinforces its leadership in autoimmune innovation, regulatory excellence, and patient-focused therapeutic design. The company’s dual emphasis on scientific precision and compliance-driven execution exemplifies the next generation of biopharma innovation—where breakthrough science, quality assurance, and patient benefit converge. As Zenas continues to advance its late-stage assets and expand its global footprint, it remains a driving force in transforming the future of autoimmune disease management through science-led and compliant innovation.
Source: Zenas BioPharma (USA) LLC press release
